personalized polyepitope plasmid DNA breast cancer vaccine

A polyepitope DNA vaccine composed of a DNA plasmid encoding multiple, highly immunogenic tumor-associated antigens (TAAs) that are specifically selected after genome profiling of the patient’s breast cancer cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration and electroporation of the personalized polyepitope plasmid DNA breast cancer vaccine, the expressed TAAs induce cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing the TAAs. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More